The significant association between LRFN4 expression and pathological stages in specific tumors, including ACC, LUAD, KIRC, LUSC, and OV, strongly indicates that LRFN4 could serve as a valuable biomarker for monitoring disease progression. This evidence concerns the gene LRFN4 and adrenal cortex carcinoma.